NCT05396742View on ClinicalTrials.gov

Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 9, 2018

Primary Completion Date

May 21, 2019

Study Completion Date

May 21, 2019

Conditions
Healthy
Interventions
DRUG

Ravulizumab

Solution for infusion or injection, as applicable

DRUG

rHuPH20

Solution for infusion

Trial Locations (1)

Unknown

Clinical Trial Site, London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY